SCHEMBL9315939

SCHEMBL9315939

CCCCCCN(C)C(=O)CCC

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHX2 P34913 5/20 0.60
▸ CNR1 P21554 1/20 0.47
▸ ALDH1A1 P00352 2/20 0.46
▸ DNM1 Q05193 3/20 0.46
▸ KDM5A P29375 2/20 0.46
▸ KDM4C Q9H3R0 2/20 0.46
▸ PHF8 Q9UPP1 1/20 0.46
▸ CES2 O00748 3/20 0.44
▸ CES1 P23141 3/20 0.44
▸ SIGMAR1 Q99720 1/20 0.44
▸ BCHE P06276 1/20 0.44
▸ ACHE P22303 1/20 0.44
▸ KDM5C P41229 1/20 0.43
▸ KDM5B Q9UGL1 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ SLC22A6 Q4U2R8 1/20 0.43
▸ SLC22A8 Q8TCC7 1/20 0.43
▸ GPR84 Q9NQS5 1/20 0.43
▸ PPARG P37231 1/20 0.43
▸ PPARD Q03181 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25885408 1.00 EPHX2 (0.60) EPHX2CNR1ALDH1A1DNM1KDM5A
SCHEMBL27514482 1.00 EPHX2 (0.60) EPHX2CNR1ALDH1A1DNM1KDM5A
SCHEMBL13964302 0.98 EPHX2 (0.57) EPHX2CNR1ALDH1A1DNM1KDM5A
SCHEMBL8702680 0.93 EPHX2 (0.62) EPHX2CNR1ALDH1A1DNM1KDM5A
SCHEMBL4885883 0.93 EPHX2 (0.62) EPHX2CNR1ALDH1A1DNM1KDM5A
SCHEMBL23343387 0.91 EPHX2 (0.70) EPHX2CNR1ALDH1A1KDM5AKDM4C
SCHEMBL5293678 0.91 EPHX2 (0.70) EPHX2CNR1ALDH1A1KDM5AKDM4C
SCHEMBL21596652 0.91 EPHX2 (0.70) EPHX2CNR1ALDH1A1KDM5AKDM4C
SCHEMBL2484953 0.91 EPHX2 (0.70) EPHX2CNR1ALDH1A1KDM5AKDM4C
SCHEMBL2482309 0.91 EPHX2 (0.70) EPHX2CNR1ALDH1A1KDM5AKDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065196-A1 Trityl Derivatives for Enhancing Mass Spectrometry OXFORD GENE TECHNOLOGY IP LIMITED (GB) 2011-03-17 — — US disclosed
US-5286752-A Antiarrhythmic diarylamidines STERLING WINTHROP INC. (US) 1994-02-15 — — US disclosed
US-4975208-A WITH FLUOROCARBON SURFACTANTS UNION OIL COMPANY OF CALIFORNIA (US) 1990-12-04 — — US disclosed
US-4923009-A STEAM AND FLUOROCARBON SURFACTANT MIXTURE WITH CONTROLLED PH UNION OIL COMPANY OF CALIFORNIA (US) 1990-05-08 — — US disclosed
US-4580633-A Increasing the flow of fluids through a permeable formation UNION OIL COMPANY OF CALIFORNIA (US) 1986-04-08 — — US disclosed
US-4567946-A BLEND OF TERTIARY AMIDE, ACID, AND WATER SOLUBLE POLYMER UNION OIL COMPANY OF CALIFORNIA (US) 1986-02-04 — — US disclosed
US-4549609-A Treating fines-containing earthen formations UNION OIL COMPANY OF CALIFORNIA (US) 1985-10-29 — — US disclosed
US-4487265-A Acidizing a subterranean reservoir UNION OIL COMPANY OF CALIFORNIA (US) 1984-12-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065196-A1 Trityl Derivatives for Enhancing Mass Spectrometry PTMS, PTMA, TST EPHX2 1516/4885CNR1 3893/4885ALDH1A1 1386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback